{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:02:42Z","timestamp":1766023362746,"version":"3.48.0"},"reference-count":38,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/cbsp3728","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T04:32:13Z","timestamp":1741062733000},"page":"824-832","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of a tumor marker gastrin-releasing peptide precursor in the patients with kidney injuries"],"prefix":"10.62347","volume":"15","author":[{"given":"Nan","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"114497","DOI":"10.1016\/j.biopha.2023.114497","article-title":"Novel insight on GRP\/GRPR axis in diseases","volume":"161","author":"Sun","year":"2023","unstructured":"Sun HL, Ma QY, Bian HG, Meng XM and Jin J. Novel insight on GRP\/GRPR axis in diseases. Biomed Pharmacother 2023; 161: 114497.","journal-title":"Biomed Pharmacother"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.ymthe.2023.06.016","article-title":"Genetic and pharmacological inhibition of GRPR protects against acute kidney injury via attenuating renal inflammation and necroptosis","volume":"31","author":"Li","year":"2023","unstructured":"Li C, Ma QY, Liu XQ, Li HD, Yu MJ, Xie SS, Ma WX, Chen Y, Wang JN, He RB, Bian HG, He Y, Gao L, Deng SS, Zang HM, Gong Q, Wen JG, Liu MM, Yang C, Chen HY, Li J, Lan HY, Jin J, Yao RS and Meng XM. Genetic and pharmacological inhibition of GRPR protects against acute kidney injury via attenuating renal inflammation and necroptosis. Mol Ther 2023; 31: 2734-2754.","journal-title":"Mol Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"115901","DOI":"10.1016\/j.bcp.2023.115901","article-title":"GRP\/GRPR signaling pathway aggravates hyperuricemia-induced renal inflammation and fibrosis via ABCG2-dependent mechanisms","volume":"218","author":"Sun","year":"2023","unstructured":"Sun HL, Bian HG, Liu XM, Zhang H, Ying J, Yang H, Zu T, Cui GQ, Liao YF, Xu MF, Meng XM and Jin J. GRP\/GRPR signaling pathway aggravates hyperuricemia-induced renal inflammation and fibrosis via ABCG2-dependent mechanisms. Biochem Pharmacol 2023; 218: 115901.","journal-title":"Biochem Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2174\/1389450116666151001112130","article-title":"Gastrin-releasing peptide receptor targeting in cancer treatment: emerging signaling networks and therapeutic applications","volume":"17","author":"Laukkanen","year":"2016","unstructured":"Laukkanen MO and Castellone MD. Gastrin-releasing peptide receptor targeting in cancer treatment: emerging signaling networks and therapeutic applications. Curr Drug Targets 2016; 17: 508-514.","journal-title":"Curr Drug Targets"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Peng S, Zhan Y, Zhang D, Ren L, Chen A, Chen ZF and Zhang H. Structures of human gastrin-releasing peptide receptors bound to antagonist and agonist for cancer and itch therapy. Proc Natl Acad Sci U S A 2023; 120: e2216230120.","DOI":"10.1073\/pnas.2216230120"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1210\/en.2011-1875","article-title":"Pro-GRP-derived peptides are expressed in colorectal cancer cells and tumors and are biologically active in vivo","volume":"153","author":"Patel","year":"2012","unstructured":"Patel O, Clyde D, Chang M, Nordlund MS, Steel R, Kemp BE, Pritchard DM, Shulkes A and Baldwin GS. Pro-GRP-derived peptides are expressed in colorectal cancer cells and tumors and are biologically active in vivo. Endocrinology 2012; 153: 1082-1092.","journal-title":"Endocrinology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/lctt.s149516","article-title":"Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response","volume":"8","author":"Wojcik","year":"2017","unstructured":"Wojcik E and Kulpa JK. Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response. Lung Cancer (Auckl) 2017; 8: 231-240.","journal-title":"Lung Cancer (Auckl)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/labmed\/lmac122","article-title":"Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with clinicopathological characteristics and chemotherapeutic outcomes of lung cancer","volume":"54","author":"Bi","year":"2023","unstructured":"Bi H, Yin L, Fang W, Song S, Wu S and Shen J. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with clinicopathological characteristics and chemotherapeutic outcomes of lung cancer. Lab Med 2023; 54: 372-379.","journal-title":"Lab Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and GRPR-Targeted PET: results from 50 patients with biochemically recurrent prostate cancer","volume":"62","author":"Baratto","year":"2021","unstructured":"Baratto L, Song H, Duan H, Hatami N, Bagshaw HP, Buyyounouski M, Hancock S, Shah S, Srinivas S, Swift P, Moradi F, Davidzon G and Iagaru A. PSMA- and GRPR-Targeted PET: results from 50 patients with biochemically recurrent prostate cancer. J Nucl Med 2021; 62: 1545-1549.","journal-title":"J Nucl Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/nep.13642","article-title":"Expression and clinical value of gastrin-releasing peptide precursor in nephropathy and chronic kidney disease","volume":"25","author":"Dai","year":"2020","unstructured":"Dai Z, Zhu J, Huang H, Fang L, Lin Y, Huang S, Xie F, Sheng N and Liang X. Expression and clinical value of gastrin-releasing peptide precursor in nephropathy and chronic kidney disease. Nephrology (Carlton) 2020; 25: 398-405.","journal-title":"Nephrology (Carlton)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.clinbiochem.2004.05.007","article-title":"ProGRP: a new biomarker for small cell lung cancer","volume":"37","author":"Molina","year":"2004","unstructured":"Molina R, Filella X and Auge JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004; 37: 505-511.","journal-title":"Clin Biochem"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.4103\/1319-2442.265466","article-title":"Serum tumor markers in advanced stages of chronic kidney diseases","volume":"30","author":"Rani","year":"2019","unstructured":"Rani BS, Suchitra MM, Srinivasa Rao PVLN and Kumar VS. Serum tumor markers in advanced stages of chronic kidney diseases. Saudi J Kidney Dis Transpl 2019; 30: 898-904.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1775190","DOI":"10.1155\/2022\/1775190","article-title":"Serum cystatin, chemokine, and gastrin-releasing peptide precursors and their clinical value in patients with chronic renal failure","volume":"2022","author":"Liu","year":"2022","unstructured":"Liu X, Cai J, Xun Z, Song Q, Wang R, Li G and Xu Z. Serum cystatin, chemokine, and gastrin-releasing peptide precursors and their clinical value in patients with chronic renal failure. Biomed Res Int 2022; 2022: 1775190.","journal-title":"Biomed Res Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1072531","DOI":"10.3389\/fonc.2022.1072531","article-title":"Changes in lung cancer-related serum tumor markers in patients with chronic kidney disease and determination of upper reference limit","volume":"12","author":"Miao","year":"2022","unstructured":"Miao Q, Cai B, Niu Q and Zhang J. Changes in lung cancer-related serum tumor markers in patients with chronic kidney disease and determination of upper reference limit. Front Oncol 2022; 12: 1072531.","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41579-020-0324-0","article-title":"Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies","volume":"18","author":"Klein","year":"2020","unstructured":"Klein RD and Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol 2020; 18: 211-226.","journal-title":"Nat Rev Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: core curriculum 2020","volume":"75","author":"Geetha","year":"2020","unstructured":"Geetha D and Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis 2020; 75: 124-137.","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","unstructured":"Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, Kullman J, Lyons PA, Merkel PA, Savage COS, Specks U and Kain R. ANCA-associated vasculitis. Nat Rev Dis Primers 2020; 6: 71.","journal-title":"Nat Rev Dis Primers"},{"key":"ref17","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, and De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS, Riella MC, Shlipak MG, Wang HY, White CT and Winearls CG. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","unstructured":"Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL and Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28.","journal-title":"Kidney Int"},{"key":"ref19","unstructured":"KDIGO GN Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2012; 2: 139-274."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T and Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.","journal-title":"Ann Intern Med"},{"key":"ref21","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved Guideline. In: CLSI Document C28-A3 (3rd Edition). 2008."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Li L, Zhang Q, Wang Y and Xu C. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer. J Clin Lab Anal 2023; 37: e24865.","DOI":"10.1002\/jcla.24865"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cca.2020.08.007","article-title":"Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer","volume":"510","author":"Yu","year":"2020","unstructured":"Yu M, Yang C, Wang S, Zeng Y, Chen Z, Feng N, Ning C, Wang L, Xue L and Zhang Z. Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer. Clin Chim Acta 2020; 510: 437-441.","journal-title":"Clin Chim Acta"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.33393\/jcb.2021.2212","article-title":"Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring","volume":"10","author":"Barchiesi","year":"2021","unstructured":"Barchiesi V, Simeon V, Sandomenico C, Cantile M, Cerasuolo D, Chiodini P, Morabito A and Cavalcanti E. Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring. J Circ Biomark 2021; 10: 9-13.","journal-title":"J Circ Biomark"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.21037\/jtd.2019.04.29","article-title":"Diagnostic value of ProGRP for small cell lung cancer in different stages","volume":"11","author":"Dong","year":"2019","unstructured":"Dong A, Zhang J, Chen X, Ren X and Zhang X. Diagnostic value of ProGRP for small cell lung cancer in different stages. J Thorac Dis 2019; 11: 1182-1189.","journal-title":"J Thorac Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/bju.12886","article-title":"Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy","volume":"115","author":"Ischia","year":"2015","unstructured":"Ischia J, Patel O, Sethi K, Nordlund MS, Bolton D, Shulkes A and Baldwin GS. Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy. BJU Int 2015; 115: 829-838.","journal-title":"BJU Int"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/08901171241232057c","article-title":"The eGFR equation","volume":"38","author":"Bervell","year":"2024","unstructured":"Bervell J. The eGFR equation. Am J Health Promot 2024; 38: 435-436.","journal-title":"Am J Health Promot"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and estimation of GFR for use in clinical practice: core curriculum 2021","volume":"78","author":"Inker","year":"2021","unstructured":"Inker LA and Titan S. Measurement and estimation of GFR for use in clinical practice: core curriculum 2021. Am J Kidney Dis 2021; 78: 736-749.","journal-title":"Am J Kidney Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/clinchem\/hvab282","article-title":"Clinical impact of the refit CKD-EPI 2021 creatinine-based eGFR equation","volume":"68","author":"Meeusen","year":"2022","unstructured":"Meeusen JW, Kasozi RN, Larson TS and Lieske JC. Clinical impact of the refit CKD-EPI 2021 creatinine-based eGFR equation. Clin Chem 2022; 68: 534-539.","journal-title":"Clin Chem"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"TK","year":"2019","unstructured":"Chen TK, Knicely DH and Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA 2019; 322: 1294-1304.","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s00216-014-7634-x","article-title":"Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay","volume":"406","author":"Torsetnes","year":"2014","unstructured":"Torsetnes SB, Broughton MN, Paus E, Halvorsen TG and Reubsaet L. Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay. Anal Bioanal Chem 2014; 406: 2733-2738.","journal-title":"Anal Bioanal Chem"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1053\/j.jrn.2023.01.007","article-title":"Association of diet-dependent systemic acid load, renal function, and serum albumin concentration","volume":"33","author":"Banerjee","year":"2023","unstructured":"Banerjee T, Sebastian A and Frassetto L. Association of diet-dependent systemic acid load, renal function, and serum albumin concentration. J Ren Nutr 2023; 33: 428-434.","journal-title":"J Ren Nutr"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/jdi.12134","article-title":"Association of serum bilirubin levels with development and progression of albuminuria, and decline in estimated glomerular filtration rate in patients with type 2 diabetes mellitus","volume":"5","author":"Toya","year":"2014","unstructured":"Toya K, Babazono T, Hanai K and Uchigata Y. Association of serum bilirubin levels with development and progression of albuminuria, and decline in estimated glomerular filtration rate in patients with type 2 diabetes mellitus. J Diabetes Investig 2014; 5: 228-235.","journal-title":"J Diabetes Investig"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Kawamoto R, Ninomiya D, Hasegawa Y, Kasai Y, Kusunoki T, Ohtsuka N and Kumagi T. Association between serum bilirubin and estimated glomerular filtration rate among elderly persons. PLoS One 2014; 9: e115294.","DOI":"10.1371\/journal.pone.0115294"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/jch.14727","article-title":"Association between bilirubin and chronic kidney disease in hypertensive patients: the China hypertension registry study","volume":"25","author":"Zhao","year":"2023","unstructured":"Zhao P, Xu H, Shi Y, Song X, Qiu G, Ding C, Zhou W, Yu C, Wang T, Zhu L, Bao H and Cheng X. Association between bilirubin and chronic kidney disease in hypertensive patients: the China hypertension registry study. J Clin Hypertens (Greenwich) 2023; 25: 1185-1192.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.atherosclerosis.2014.03.015","article-title":"Low serum bilirubin concentration is a predictor of chronic kidney disease","volume":"234","author":"Tanaka","year":"2014","unstructured":"Tanaka M, Fukui M, Okada H, Senmaru T, Asano M, Akabame S, Yamazaki M, Tomiyasu K, Oda Y, Hasegawa G, Toda H and Nakamura N. Low serum bilirubin concentration is a predictor of chronic kidney disease. Atherosclerosis 2014; 234: 421-425.","journal-title":"Atherosclerosis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/ckj\/sfac120","article-title":"Serum bilirubin and kidney function: a Mendelian randomization study","volume":"15","author":"Park","year":"2022","unstructured":"Park S, Lee S, Kim Y, Lee Y, Kang MW, Kim K, Kim YC, Han SS, Lee H, Lee JP, Joo KW, Lim CS, Kim YS and Kim DK. Serum bilirubin and kidney function: a Mendelian randomization study. Clin Kidney J 2022; 15: 1755-1762.","journal-title":"Clin Kidney J"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/2\/ajcr0159224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:48Z","timestamp":1766023068000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/2\/ajcr0159224.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/cbsp3728","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2025]]}}}